Predictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted-release formulation budesonide.

ABSTRACT:

Background

Targeted release formulation (TRF) budesonide (Nefecon), targeting galactose-deficient immunoglobulin A1 (Gd-IgA1) production and IgA immune complex formation, has been approved for IgA nephropathy (IgAN) treatment. In this study we explored whether early changes in these biomarkers can predict the clinical response to Nefecon therapy.

Methods

Plasma samples from 27 IgAN patients treated with Nefecon and followed at least 6 months were collected during routine visits. We measured the levels of Gd-IgA1 and poly-IgA during the treatment, analysing the association between their baseline levels or changes and proteinuria reduction.

Results

The mean proteinuria level was 1.3 ± 0.8 g/day and the estimated glomerular filtration rate was 47.1 ± 21.7 ml/min/1.73 m

SUBMITTER: Chen Q 

PROVIDER: S-EPMC12268327 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature